Carrier

UnitedHealthcare

UnitedHealth Group · Drug benefit: Optum Rx · 5 documents cited · Read September 2026

Says in its own program document that weight-loss coverage is optional, and sells it to employers who choose to buy it.

Denise Ramirez, Coverage Editor · Who writes this

UnitedHealthcare answers the question most coverage pages dodge, and it answers it in the first paragraph of its own program document rather than in a footnote.

Its weight-loss prior authorization program opens by describing itself as optional — something put in place for clients and businesses that have chosen to cover these drugs. Two companion programs exist for everyone else, and both say in writing that weight-loss medications are typically excluded from the benefit. So before any body mass index number matters, there is a purchasing question that was settled by an employer, and the criteria you can read online only apply once that question came out one particular way.

The second thing the documents show is that UnitedHealthcare's BMI floor is not one number. The general program admits patients at 30, or at 27 with a weight-related condition. A separate section of the same document, written for one state's fully insured essential health benefits plans, sets the floor at 40. The stricter number sits in the state section, which is the opposite of what most readers would guess.

What none of it tells you is which program your plan bought. We looked and could not find a public document that maps a member to one, so this page does not pretend to.

Start with the sentence that decides it

UnitedHealthcare's weight-loss program is not a rule that applies to its members. It is a product an employer can add, and the document says so about itself in its opening line.

The proof is in what happens to everyone whose employer did not add it. Two separate programs cover Wegovy and Zepbound for people whose plans exclude weight loss, and they reach the drug through a different door: cardiovascular risk reduction, liver disease, or sleep apnea. Neither of them will approve the drug for weight loss, because that is the thing the plan excluded.

For a reader holding a denial, the useful question is which of those two situations produced it. A denial that turns on a missing benefit is not answered by more clinical evidence. A denial that turns on a criterion sometimes is.

Why the strictest BMI number is a state's

The general program takes patients at a BMI of 30, or 27 with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea. That is the number most readers will find first.

Then the same document opens a second section for North Dakota fully insured essential health benefits plans, small group and individual, and sets the floor there at 40. The background note explains why that section exists at all: the program is also designed to meet regulatory requirements in California, New Mexico, North Dakota and New York. A state law requiring coverage is not the same thing as a state law setting the terms of it, and here the terms came out tighter.

The practical point is that where a plan is written can change the number, and the number is easy to read off the wrong section.

Do not check the drug list to answer this

It is a natural move to look up your drug on the plan's prescription drug list. On this question it will mislead you, and we checked rather than assuming.

We read the whole of UnitedHealthcare's Advantage 3-Tier Prescription Drug List effective September 1, 2026 — 209,394 characters of it, extracted twice by two different methods so a formatting quirk could not fake an absence. Wegovy, Zepbound, Saxenda, Foundayo, Qsymia and Contrave appear zero times. So do the words "weight" and "obes". The diabetes GLP-1s are there: Ozempic and Mounjaro both appear, each marked for prior authorization and quantity limits, and insulin appears 27 times, which is how we know the search was working.

A list that never mentions these drugs cannot tell you whether they are covered. The document that settles it is the program your employer bought, and the plan description that says whether the benefit exists.

What the approval actually buys you

The program does not approve these drugs open-endedly, and the first authorization is short. Wegovy injection, Wegovy tablet and Wegovy HD get five months. Foundayo, Xenical and Zepbound get six. Contrave, Qsymia and Saxenda get four, and the older stimulant appetite suppressants get three.

Renewal is a measured test rather than a check-in. Most drugs need at least 5 percent of baseline body weight lost, with lower bars written for two of them, and lifestyle modification has to have continued. Meet it and the next authorization runs twelve months.

That matters for planning more than for arguing. The first review lands within months of starting, and the number it turns on is measured from your weight at the start of therapy.

Where the appeal deadlines are, and are not

We looked for a single national filing window in UnitedHealthcare's own 2026 Care Provider Administrative Guide and did not find one. What the guide publishes instead are windows attached to particular states and products.

Two of them are 180 days. Under its Oxford commercial supplement, Connecticut members get 180 days from receipt of an adverse determination to start a utilization review appeal, and New York member appeals get 180 days from receipt of the initial adverse determination. Both clocks run from receipt, not from the date printed on the notice.

Do not carry either number to a state it was not written for. The window that binds you is on your own denial notice and in your plan document, and this page does not guess at it.

Every claim above, with the document behind it

These are the policies we opened and the month we opened them. Each one carries its own policy number and effective date on its face, and those are printed here as the document shows them.

UnitedHealthcare describes its weight-loss coverage as something an employer buys rather than something its members have. The program's own background section opens: "This is an optional program that is put in place for clients or businesses that have elected to cover weight loss products with Prior Authorization/Notification."

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Notification – Plans with Weight Loss/Appetite Suppression Medication Coverage" (2026 P 1114-22), effective September 2026 · source

A separate program exists for plans that did not buy it, and it says why: "Medications for the purpose of weight loss are typically a benefit exclusion. The program allows for coverage of Wegovy injection or tablet for the cardiovascular risk reduction indication and Wegovy injection for MASH." It will not approve Wegovy for weight loss, because that is the thing those plans exclude.

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets – Cardiovascular Risk Reduction and MASH Only" (2026 P 1445-4), effective May 2026 · source

Zepbound has the same arrangement through a different door. Its non-formulary program repeats that "Medications for the purpose of weight loss are typically a benefit exclusion," and then states: "The program allows for coverage of Zepbound for obesity with obstructive sleep apnea." It requires a sleep study, a BMI of at least 30, and either continued symptoms despite adherent positive airway pressure therapy or a reason you cannot use it.

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Zepbound (tirzepatide) – Obstructive Sleep Apnea Only" (2026 P 1475-3), effective September 2026 · source

There is more than one BMI floor in the same document, and the higher one is written for a single state. The general criteria admit a patient with "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile", or a BMI of at least 27 with a weight-related comorbidity. The section headed "Coverage Criteria for North Dakota Fully Insured EHB (Small Group and Individual) Plans" instead requires "Body Mass Index (BMI) ≥ 40 kg/m2 or for pediatric patients a BMI > 120% of 95th percentile".

The program says which states it was built around. Its background section states that it "is also designed to meet regulatory requirements for coverage of weight loss medications in California, New Mexico, North Dakota Essential Health Benefits (EHB) and New York." Where you live can therefore decide whether the benefit exists in a fully insured plan and, in North Dakota's case, which threshold applies to it.

None of these drugs is on the standard commercial drug list, so looking there answers nothing. We searched the whole of the Advantage 3-Tier Prescription Drug List effective September 1, 2026 — 209,394 characters, extracted twice by two different methods — and Wegovy, Zepbound, Saxenda, Foundayo, Qsymia and Contrave each appear zero times, as do the words "weight" and "obes". In the same searches Ozempic appears twice and Mounjaro twice, both listed under "Diabetes - Non-insulin agents" at tier 2 with prior authorization and quantity limits, and insulin appears 27 times.

UnitedHealthcare, "Your 2026 Prescription Drug List, Advantage 3-Tier", effective September 2026 · source

First approvals are short and renewal is measured. The program issues five months for "Wegovy injection or tablet, Wegovy HD", six for "Foundayo, Xenical or Zepbound", four for Contrave, Qsymia or Saxenda, and three for the older stimulant appetite suppressants. To reauthorize, most drugs need "Weight loss of ≥ 5% of baseline body weight" — 3 percent for Qsymia, 4 percent for Saxenda — plus continued lifestyle modification, and the renewal then runs twelve months.

The appeal windows UnitedHealthcare publishes are attached to states, not to the company. Searching its 2026 Care Provider Administrative Guide, the member filing windows we found sit under state headings: for Connecticut members, "UR appeals must be initiated within 180 days from receipt of an adverse determination (i.e., receipt of the determination notice)", and under New York member appeals, "Member appeals must be submitted to us or our delegate within 180 days from the receipt of the initial adverse UR determination." We found no single nationwide commercial member deadline in the guide, so this page states none.

UnitedHealthcare, "2026 UnitedHealthcare Care Provider Administrative Guide", effective 2026 · source

What these documents cannot tell you

Everything above is what UnitedHealthcare publishes. None of it establishes what your own plan does, and the gap between those two things is wider than a carrier policy makes it look.

Nothing UnitedHealthcare publishes tells you which program your plan is on. The optional weight-loss program, the two non-formulary programs and the North Dakota section are all public, and no public document maps a member to one of them.
The drug list we searched is one of many. UnitedHealthcare publishes dozens of prescription drug lists — separate ones by tier count, by market and by state — and our census covers the Advantage 3-Tier list named above, not all of them.
A self-funded employer plan can set its own terms. The name on the card does not settle whose criteria govern you or whether state insurance law reaches the plan at all.
The 180-day windows above are Connecticut and New York provisions quoted from a national guide. They are not a nationwide deadline, and this page does not apply them to any other state.
None of this is legal or medical advice, and this page does not predict how an appeal will come out. Your plan document and the notice you received govern your case.

Where this comes from

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Notification – Plans with Weight Loss/Appetite Suppression Medication Coverage" (2026 P 1114-22), effective September 2026 — www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-ph
UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets – Cardiovascular Risk Reduction and MASH Only" (2026 P 1445-4), effective May 2026 — www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-ph
UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Zepbound (tirzepatide) – Obstructive Sleep Apnea Only" (2026 P 1475-3), effective September 2026 — www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-ph
UnitedHealthcare, "Your 2026 Prescription Drug List, Advantage 3-Tier", effective September 2026 — www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/pharmacy-pdl-3t-adv-s
UnitedHealthcare, "2026 UnitedHealthcare Care Provider Administrative Guide", effective 2026 — www.uhcprovider.com/content/dam/provider/docs/public/admin-guides/2026-U

Where to go next

American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what UnitedHealthcare publishes. It is not affiliated with UnitedHealth Group, and your own plan documents and your own notice govern your case. Policies carry effective dates and change — read the sources before you act.